Compressed Sensing Accelerated Magnetic Resonance Spectroscopic Imaging

abstract: Magnetic resonance spectroscopic imaging (MRSI) is a valuable technique for assessing the in vivo spatial profiles of metabolites like N-acetylaspartate (NAA), creatine, choline, and lactate. Changes in metabolite concentrations can help identify tissue heterogeneity, providing prognostic and diagnostic information to the clinician. The increased uptake of glucose by solid tumors as compared to normal tissues and its conversion to lactate can be exploited for tumor diagnostics, anti-cancer therapy, and in the detection of metastasis. Lactate levels in cancer cells are suggestive of altered metabolism, tumor recurrence, and poor outcome. A dedicated technique like MRSI could contribute to an improved assessment of metabolic abnormalities in the clinical setting, and introduce the possibility of employing non-invasive lactate imaging as a powerful prognostic marker. However, the long acquisition time in MRSI is a deterrent to its inclusion in clinical protocols due to associated costs, patient discomfort (especially in pediatric patients under anesthesia), and higher susceptibility to motion artifacts. Acceleration strategies like compressed sensing (CS) permit faithful reconstructions even when the k-space is undersampled well below the Nyquist limit. CS is apt for MRSI as spectroscopic data are inherently sparse in multiple dimensions of space and frequency in an appropriate transform domain, for e.g. the wavelet domain. The objective of this research was three-fold: firstly on the preclinical front, to prospectively speed-up spectrally-edited MRSI using CS for rapid mapping of lactate and capture associated changes in response to therapy. Secondly, to retrospectively evaluate CS-MRSI in pediatric patients scanned for various brain-related concerns. Thirdly, to implement prospective CS-MRSI acquisitions on a clinical magnetic resonance imaging (MRI) scanner for fast spectroscopic imaging studies. Both phantom and in vivo results demonstrated a reduction in the scan time by up to 80%, with the accelerated CS-MRSI reconstructions maintaining high spectral fidelity and statistically insignificant errors as compared to the fully sampled reference dataset. Optimization of CS parameters involved identifying an optimal sampling mask for CS-MRSI at each acceleration factor. It is envisioned that time-efficient MRSI realized with optimized CS acceleration would facilitate the clinical acceptance of routine MRSI exams for a quantitative mapping of important biomarkers.Dissertation/ThesisDoctoral Dissertation Bioengineering 201

Quantitative NMR-Based Biomedical Metabolomics: Current Status and Applications

Nuclear Magnetic Resonance (NMR) spectroscopy is a quantitative analytical tool commonly utilized for metabolomics analysis. Quantitative NMR (qNMR) is a field of NMR spectroscopy dedicated to the measurement of analytes through signal intensity and its linear relationship with analyte concentration. Metabolomics-based NMR exploits this quantitative relationship to identify and measure biomarkers within complex biological samples such as serum, plasma, and urine. In this review of quantitative NMR-based metabolomics, the advancements and limitations of current techniques for metabolite quantification will be evaluated as well as the applications of qNMR in biomedical metabolomics. While qNMR is limited by sensitivity and dynamic range, the simple method development, minimal sample derivatization, and the simultaneous qualitative and quantitative information provide a unique landscape for biomedical metabolomics, which is not available to other techniques. Furthermore, the non-destructive nature of NMR-based metabolomics allows for multidimensional analysis of biomarkers that facilitates unambiguous assignment and quantification of metabolites in complex biofluids

Developing an Integrative Glycobiology Workflow for the Identification of Disease Markers for Pancreatic Cancer

A deeper understanding of dysregulated glycosylation in pancreatic cancer can provide insights into disease mechanisms and the identification of novel disease markers. Recent improvements in mass spectrometry techniques have been instrumental in profiling biologically relevant tissue sections in order to identify disease marker candidates, but have either not yet been adopted for studying glycosylation or applied directly to pancreatic cancer. In the dissertation herein, new methods have been developed and adapted to the study of aberrant glycosylation in pancreatic cancer, with the ultimate goal of identifying novel disease marker candidates. For the first time, we describe a mass spectrometry imaging approach to study the localization of N-glycans. This technique demonstrated a histology-derived localization of N-glycans across tissue sections, with identifications displaying remarkable consistency with documented studies. Furthermore, the technique provides superior structural information compared to preexisting methodologies. In the analysis of diseased specimen, changes in glycosylation can be linked to aberrations in glycosyltransferase expression. When applied to pancreatic cancer in a high-throughput and high-dimensional analysis, panels of glycans displayed an improved ability to differentiate tumor from non-tumor tissues compared to current disease markers. Furthermore, the data suggest that glycosylation can identify premalignant lesions, as well as differentiate between malignant and benign conditions. These observations overcome significant limitations that hinder the efficacy of current disease markers. In an effort to link aberrant glycosylation to the modified protein, a subset of glycosylated proteins were enriched and analyzed by mass spectrometry to identify proteins that are integral to disease progression and can be probed for the early detection of pancreatic cancer. Known disease markers were among the glycoproteins identified, validating the utility of the enrichment and detection strategy outlined. This approach also differentiated the role of N- and O-glycosylation in antigen expression. Finally, we outline an integrated workflow that takes advantage of the unique capabilities of high resolution mass spectrometers. This workflow can capitalize on prior glycomic and proteomic experiments to provide a comprehensive analysis of dysregulated protein glycosylation in pancreatic cancer

Metabolomics for mitochondrial and cancer studies

AbstractMetabolomics, a high-throughput global metabolite analysis, is a burgeoning field, and in recent times has shown substantial evidence to support its emerging role in cancer diagnosis, cancer recurrence, and prognosis, as well as its impact in identifying novel cancer biomarkers and developing cancer therapeutics. Newly evolving advances in disease diagnostics and therapy will further facilitate future growth in the field of metabolomics, especially in cancer, where there is a dire need for sensitive and more affordable diagnostic tools and an urgency to develop effective therapies and identify reliable biomarkers to predict accurately the response to a therapy. Here, we review the application of metabolomics in cancer and mitochondrial studies and its role in enabling the understanding of altered metabolism and malignant transformation during cancer growth and metastasis. The recent developments in the area of metabolic flux analysis may help to close the gap between clinical metabolomics research and the development of cancer metabolome. In the era of personalized medicine with more and more patient specific targeted therapies being used, we need reliable, dynamic, faster, and yet sensitive biomarkers both to track the disease and to develop and evolve therapies during the course of treatment. Recent advances in metabolomics along with the novel strategies to analyze, understand, and construct the metabolic pathways opens this window of opportunity in a very cost-effective manner. This article is part of a Special Issue entitled: Bioenergetics of Cancer

Detection of Hepatocellular Carcinoma in Hepatitis C Patients: Biomarker Discovery by LC-MS

Hepatocellular carcinoma (HCC) accounts for most cases of liver cancer worldwide; contraction of hepatitis C (HCV) is considered a major risk factor for liver cancer even when individuals have not developed formal cirrhosis. Global, untargeted metabolic profiling methods were applied to serum samples from patients with either HCV alone or HCC (with underlying HCV). The main objective of the study was to identify metabolite based biomarkers associated with cancer risk, with the long term goal of ultimately improving early detection and prognosis. Serum global metabolite profiles from patients with HCC (n=37) and HCV (n=21) were obtained using high performance liquid chromatography-mass spectrometry (HPLC-MS) methods. The selection of statistically significant metabolites for partial least-squares discriminant analysis (PLS-DA) model creation based on biological and statistical significance was contrasted to that of a traditional approach utilizing p-values alone. A PLS-DA model created using the former approach resulted in a model with 92% sensitivity, 95% specificity, and an AUROC of 0.93. A series of PLS-DA models iteratively utilizing three to seven metabolites that were altered significantly (p<0.05) and sufficiently (FC≤0.7 or FC≥1.3) showed the best performance using p-values alone, the PLS-DA model was capable of generating 73% sensitivity, 95% specificity, and an AUROC of 0.92. Metabolic profiles derived from LC-MS readily distinguish patients with HCC and HCV from those with HCV only. Differences in the metabolic profiles between highrisk individuals and HCC indicate the possibility of identifying the early development of liver cancer in at risk patients. The use of biological significance as a selection process prior to PLSDA modeling may offer improved probabilities for translation of newly discovered biomarkers to clinical application

Metabolomics contributions to targeted and untargeted clinical analysis by chromatography and mass spectrometry

La investigación desarrollada en esta Tesis Doctoral se centró en realizar contribuciones en el ámbito del análisis clínico a través de estrategias metabolómicas tanto orientadas como globales en diferentes tipos de muestras biológicas mediante cromatografía de líquidos (LC) y espectrometría de masas (MS). Para ello primeramente se revisó exhaustiva y críticamente la bibliografía para conocer el estado del tratamiento de la orina como muestra y de los métodos de análisis de aire exhalado condensado, dos de los biofluidos utilizados en el desarrollo de esta Tesis. Además, se optimizaron métodos de análisis orientado para mejorar la cuantificación tanto de compuestos con potencial biomarcador como de fármacos y sus metabolitos para su aplicación en el diagnóstico y seguimiento de enfermedades o tratamientos. También se analizaron de forma global biofluidos para, (a) estudiar y optimizar el tratamiento de una muestra escasamente utilizada en el área clínica (el aire exhalado condensado –EBC), (b) identificar metabolitos con potencial predictivo para ayudar en el diagnóstico del cáncer de próstata utilizando la orina como muestra, y (c) mejorar y acelerar el tratamiento de datos a través de herramientas quimiométricas desarrolladas para combinar en una única matriz los datos obtenidos mediante ionización positiva y negativa en espectrometría de masas

Applications of advanced spectroscopic imaging to biological tissues

The objectives of this research were to develop experimental approaches that can be applied to classify different stages of malignancy in routine formalin-fixed and paraffin-embedded tissues and to optimise the imaging approaches using novel implementations. It is hoped that the approach developed in this research may be applied for early cancer diagnostics in clinical settings in the future in order to increase cancer survival rates. Infrared spectroscopic imaging has recently shown to have great potential as a powerful method for the spatial visualization of biological tissues. This spectroscopic technique does not require sample labelling because its chemical specificity allows the differentiation of biocomponents to be achieved based on their chemical structures. Experiments were performed on 3-µm thick prostate and colon tissues that were deposited on 2 mm-calcium fluoride (CaF2) which were subsequently deparaffinised. The samples were measured under IR microscopes, in both transmission and attenuated total reflection (ATR) mode. In transmission, thermo-spectroscopic imaging of the prostate samples was first carried out to investigate the potential of thermography to complement the information obtained from IR spectral. Spectroscopic imaging has made the acquisition of chemical map of a sample possible within a short time span since this approach facilitates the simultaneous acquisition of thousands of spatially resolved infrared spectra. Spectral differences in the lipid region (3000 -2800 cm-1) were identified between cancer and benign regions within prostate tissues. The governing spectral band for classification was anti-symmetric stretching of CH2 (2921 cm-1) from PCA analysis. Nonetheless, the difference in tissue emissivity at room temperature was minimal, thus the contrast in the thermal image is low for intra-tissue classification. Besides, the thermal camera could only capture IR light between 3333-2000 cm-1. To record spectral data between 3900 - 900 cm-1 (mid-IR), Fourier transform infrared (FTIR) spectroscopic imaging was used to classify the different stages of colon disease. An automated processing framework was developed, that could achieve an overall classification accuracy of 92.7%. The processing steps included unsupervised k-means clustering of lipid bands, followed by Random Forest (RF) classification using the ‘fingerprint’ region of the data. The implementation of a correcting lens and the effect of the RMieS-EMSC correction on the tissue spectra were also investigated, which showed that computational RMieS-EMSC correction was more effective at removing spectral artefacts than the correcting lens. Furthermore, the effect of the fluctuations of surrounding humidity where the experiments were carried out was studied by using various supersaturated salt solutions. Significant peak changes of the phosphate band were observed, most notably the peak shift of the anti-symmetric stretching of phosphate bands from 1230 cm-1 to 1238 cm-1 was observed. By regulating and controlling humidity at its lowest, the classification accuracy of the colon specimens was improved without having to resort to alteration on the RF machine learning algorithm. In the ATR mode, additional apertures were introduced to the FTIR microscope, as a novel means of depth profiling the prostate tissue samples by changing the angle of incidence of IR light beam. Despite the successful attempts in capturing the qualitative information on the change of tissue morphology with the depth of penetration (dp), the spectral data were not suitable for further processing with machine learning as dp changes with wavelengths. Apart from the apertures, a ‘large-area’ germanium (Ge) crystal was introduced to enable simultaneous mapping and imaging of the colon tissue samples. Many advantages of this new implementation were observed, which included improvement in signal-to-noise ratio, uniform distribution, and no impression left on the sample. The research done in this thesis set a groundwork for clinical diagnosis and the novel implementations were transferable to studies of other samples.Open Acces